+ Site Statistics
References:
52,572,879
Abstracts:
28,705,754
PMIDs:
27,750,366
DOIs:
25,464,004
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Statin therapy and risks for death and hospitalization in chronic heart failure



Statin therapy and risks for death and hospitalization in chronic heart failure



JAMA 296(17): 2105-2111



Whether statin therapy has beneficial effects on clinical outcomes in patients with heart failure is unclear. To evaluate the association between initiation of statin therapy and risks for death and hospitalization among adults with chronic heart failure. Propensity-adjusted cohort study of adults diagnosed with heart failure who were eligible for lipid-lowering therapy but had no previous known statin use, within an integrated health care delivery system in northern California between January 1, 1996, and December 31, 2004. Statin use was estimated from filled outpatient prescriptions in pharmacy databases. All-cause death and hospitalization for heart failure during a median of 2.4 years of follow-up. We examined the independent relationships between statin therapy and risks for adverse events overall and stratified by the presence or absence of coronary heart disease after multivariable adjustment for potential confounders. Among 24,598 adults diagnosed with heart failure who had no prior statin use, those initiating statin therapy (n = 12,648; 51.4%) were more likely to be younger, male, and have known cardiovascular disease, diabetes, and hypertension. There were 8235 patients who died. Using an intent-to-treat approach, incident statin use was associated with lower risks of death (age- and sex-adjusted rate of 14.5 per 100 person-years with statin therapy vs 25.3 per 100 person-years without statin therapy; adjusted hazard ratio, 0.76 [95% confidence interval, 0.72-0.80]) and hospitalization for heart failure (age- and sex-adjusted rate of 21.9 per 100 person-years with statin therapy vs 31.1 per 100 person-years without statin therapy; adjusted hazard ratio, 0.79 [95% confidence interval, 0.74-0.85]) even after adjustment for the propensity to take statins, cholesterol level, use of other cardiovascular medications, and other potential confounders. Incident statin use was associated with lower adjusted risks of adverse outcomes in patients with or without known coronary heart disease. Among adults diagnosed with heart failure who had no prior statin use, incident statin use was independently associated with lower risks of death and hospitalization among patients with or without coronary heart disease.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012889092

Download citation: RISBibTeXText

PMID: 17077375

DOI: 10.1001/jama.296.17.2105


Related references

Statin Therapy and Risks for Death and Hospitalization in Chronic Heart Failure. Yearbook of Medicine 2007: 357-359, 2007

Statin therapy and risks for death and hospitalization in chronic heart failure (vol 296, pg 2105, 2006). JAMA (Journal of the American Medical Association) 297(10): 1062, 2007

Statin use and risks for death and hospitalization in chronic heart failure. JAMA 297(10): 1057; Author Reply 1058-1057; Author Reply 1058, 2007

Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 113(23): 2713-2723, 2006

Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure. The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Yearbook of Cardiology 2007: 324-326, 2007

The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine 168(15): 1699-1704, 2008

Gender differences in statin prescription rates, adequacy of dosing, and association of statin therapy with outcome after heart failure hospitalization: a retrospective analysis in a community setting. European Journal of Clinical Pharmacology 72(3): 311-319, 2016

Cardiac resynchronization therapy reduced all-cause death and hospitalization in chronic heart failure. Acp Journal Club 141(3): 60, 2004

Statins and risks for death and hospitalization in heart failure. 2007

Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology 47(11): 2326-2331, 2006

Risks of death and hospitalization in heart failure patients receiving carvedilol versus metoprolol tartrate A retrospective claims-based study. Journal of the American College of Cardiology 43(5 Supplement A): 196A, March 3, 2004

Statin therapy blunts inflammatory activation and improves prognosis and left ventricular performance assessed by Tissue Doppler Imaging in subjects with chronic ischemic heart failure: results from the Daunia Heart Failure Registry. Clinics 66(5): 777-784, 2012

Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. JAMA Cardiology 2018, 2018

The case for statin therapy in chronic heart failure. Yearbook of Cardiology 2008: 394-395, 2008

Statin therapy for patients with chronic heart failure. American Journal of Cardiology 98(5): 707, 2006